BR112021018156A2 - Antagonistas de ngf para uso médico - Google Patents

Antagonistas de ngf para uso médico

Info

Publication number
BR112021018156A2
BR112021018156A2 BR112021018156A BR112021018156A BR112021018156A2 BR 112021018156 A2 BR112021018156 A2 BR 112021018156A2 BR 112021018156 A BR112021018156 A BR 112021018156A BR 112021018156 A BR112021018156 A BR 112021018156A BR 112021018156 A2 BR112021018156 A2 BR 112021018156A2
Authority
BR
Brazil
Prior art keywords
ngf
medical use
ngf antagonists
polypeptides
trka
Prior art date
Application number
BR112021018156A
Other languages
English (en)
Inventor
Fawn Qian
Hangjun Zhan
Lam Nguyen
Qingyi Chu
Richard Chin
Jiann Li Shyr
Original Assignee
Kindred Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindred Biosciences Inc filed Critical Kindred Biosciences Inc
Publication of BR112021018156A2 publication Critical patent/BR112021018156A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a várias modalidades relacionadas a polipeptídeos trka ecd de espécies de animais de companhia que se ligam a ngf. esses polipeptídeos podem ser usados em métodos para tratar a condição induzida por ngf relacionada à dor crônica e/ou dor inflamatória em animais de companhia, como caninos, felinos e equinos.
BR112021018156A 2019-03-20 2020-03-20 Antagonistas de ngf para uso médico BR112021018156A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821438P 2019-03-20 2019-03-20
PCT/US2020/023846 WO2020191289A1 (en) 2019-03-20 2020-03-20 Ngf antagonists for medical use

Publications (1)

Publication Number Publication Date
BR112021018156A2 true BR112021018156A2 (pt) 2021-11-16

Family

ID=72521232

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018156A BR112021018156A2 (pt) 2019-03-20 2020-03-20 Antagonistas de ngf para uso médico

Country Status (10)

Country Link
US (1) US20220169740A1 (pt)
EP (1) EP3941933A4 (pt)
JP (1) JP2022525754A (pt)
KR (1) KR20220066002A (pt)
CN (1) CN113840831A (pt)
AU (1) AU2020240120A1 (pt)
BR (1) BR112021018156A2 (pt)
CA (1) CA3133104A1 (pt)
MX (1) MX2021011335A (pt)
WO (1) WO2020191289A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020139984A1 (en) * 2018-12-27 2020-07-02 Kindred Biosciences, Inc. Igg fc variants for veterinary use
KR20230005156A (ko) * 2020-04-17 2023-01-09 조에티스 서비시즈 엘엘씨 개과 항체 변이체
CA3227716A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
AU2022369106A1 (en) * 2021-10-21 2024-04-11 Petmedix Ltd Proteins comprising the extracellular domain of p75ntr
US11608371B1 (en) 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules
WO2024165872A1 (en) * 2023-02-09 2024-08-15 Petmedix Ltd Therapeutic molecules comprising variants of the extracellular domain of p75 neurotrophin receptor (p75ntr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807781D0 (en) * 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
WO2007059574A1 (en) * 2005-11-23 2007-05-31 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
US7342146B2 (en) * 2006-01-11 2008-03-11 Industrial Technology Research Institute Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
GB201308738D0 (en) * 2013-05-15 2013-06-26 Polytherics Ltd Novel polymer conjugates
EP3668536A4 (en) * 2017-08-15 2021-05-26 Kindred Biosciences, Inc. VARIANTS OF IGG FC FOR VETERINARY USE
WO2020139984A1 (en) * 2018-12-27 2020-07-02 Kindred Biosciences, Inc. Igg fc variants for veterinary use

Also Published As

Publication number Publication date
WO2020191289A1 (en) 2020-09-24
KR20220066002A (ko) 2022-05-23
JP2022525754A (ja) 2022-05-19
CA3133104A1 (en) 2020-09-24
EP3941933A4 (en) 2023-07-26
AU2020240120A1 (en) 2021-09-30
MX2021011335A (es) 2022-01-06
CN113840831A (zh) 2021-12-24
EP3941933A1 (en) 2022-01-26
US20220169740A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
BR112021018156A2 (pt) Antagonistas de ngf para uso médico
BR112019004733A2 (pt) métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
MX2019012570A (es) Molecula del receptor de interleucina 4/interleucina 13 para uso veterinario.
MX2021004313A (es) Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
MX2021002971A (es) Anticuerpos del receptor anti-interleucina 4 para uso veterinario.
BRPI0923855A8 (pt) Ácido lipóico, e, composição de ração de animal de estimação
CY1122987T1 (el) Αντισωματα εναντι αμυλοειδους βητα
EA201991643A1 (ru) Человеческие антитела к токсину гемолизину а s.aureus
BR112018068898A2 (pt) anticorpo ou fragmento e seus usos, animal transgênico, hibridoma, vetor, composição farmacêutica e seu uso, método para modular uma doença, método para tratar perda de peso, método para modular atividade
BR112018074978A2 (pt) anticorpos para alfa-sinucleína e usos dos mesmos
AR061170A1 (es) Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf)
BR112012016146A2 (pt) uso de piruvatos na preparação de composições para animais de estimação
BR112021011642A2 (pt) Variantes de igg fc para uso veterinário
BR112019001704A2 (pt) melhorias no desempenho de crescimento em sistemas de pastagem ou de confinamento
BR112018072066A2 (pt) moléculas de ligação específicas para fcgamariia e uso das mesmas
MX2019007350A (es) Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina.
MX2022013149A (es) Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario.
CR20190569A (es) Métodos para la determinación del género de embriones aviares en huevo sin eclosionar y medio de los mismos
BR112018012660A2 (pt) composto, sal, composto sólido, polimorfo a, polimorfo b, polimorfo c, polimorfo d, composição, método de inibição da atividade de gls1 em uma amostra biológica, métodos de tratamento de um distúrbio mediado por gls1 em um sujeito necessitado, composto, sal, solvato ou polimorfo, e uso de um composto, sal, solvato ou polimorfo
BRPI0923783A8 (pt) Métodos para induzir perda de gordura corporal, e para aumentar a percentagem de massa de músculo magro em um animal de estimação
MX2022002360A (es) Anticuerpos de anti-il31 para uso veterinario.
BR112019011461A2 (pt) terapia celular à base de nk melhorada
AR103555A1 (es) Composiciones y métodos para el uso crónico de un compuesto para aumentar el peso
BR112021026797A2 (pt) Composição alimentar para animais
JP1721735S (ja) ねじり型ペット用おやつ